Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epigenetic Priming in Newly Diagnosed AML
NCT03164057Phase 2Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jun 2017
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, decitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by St. Jude Children's Research Hospital. Started Jun 2017; status: active, not recruiting.
02
Drugs
azacitidinedecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03164057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164057.